Tempest Therapeutics (TPST) Net Equity Issued and Repurchased (2012 - 2025)

Tempest Therapeutics has reported Net Equity Issued and Repurchased for 12 years, with the latest figure at $1.0 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased fell 94.88% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (down 89.65% YoY) and the FY2025 annual result came in at $6.0 million, down 78.86% from the prior year.
• Net Equity Issued and Repurchased eased to $1.0 million in Q4 2025 per TPST's latest filing, from $3.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $34.3 million in Q4 2023 and troughed at -$49000.0 in Q4 2021.
• A 5-year average of $6.4 million and a median of $1.4 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 286141.67% in 2023, down 96.86% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at -$49000.0 in 2021, then surged by 124.49% to $12000.0 in 2022, then jumped by 286141.67% to $34.3 million in 2023, then tumbled by 41.33% to $20.2 million in 2024, then tumbled by 94.88% to $1.0 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $1.0 million, $3.6 million, and $1.4 million for Q4 2025, Q2 2025, and Q1 2025 respectively.